Blend is developing novel cancer therapeutics designed to overcome biological barriers for treating cancer. We create novel cancer drugs designed to address the challenges that limit the efficacy and tolerability of cancer drugs in use today, which include: targeting of cancer cells selectively, sufficiently accumulating drug at the tumor, achieving potent cell-killing activity with patient tolerability, and penetrating into dense tumor tissue.
Blend’s innovative medicines overcome biological barriers with new targeting and cancer-fighting properties based on a proprietary suite of miniaturized biologic drug conjugate (mBDC) and nanoparticle technologies. Our skilled and inventive approach to cancer drug development is evident in two distinct advances in cancer therapeutics:
- The Pentarin platform is comprised of Blend’s proprietary technology that creates novel, miniaturized biologic drug conjugates (mBDCs). These mBDCs are comprised of a proprietary targeting ligand linked to a potent cell-killing agent, with the additional therapeutic features conferred by encapsulation into patented nanoparticles. The result is a product engine enabling us to develop novel drug conjugates with unprecedented ability to therapeutically penetrate deep inside the tumor tissue and specifically target tumor cells. In our R&D process we optimize these properties for superior efficacy in fighting cancer. Blend’s first Pentarin drug candidate is BTP-277, which is in preclinical development for solid tumors.
- A personalized Platinum therapeutic, BTP-114, is Blend’s lead clinical candidate. This novel therapeutic was discovered by Blend’s R&D team including the expertise of the company’s founder, Professor Stephen Lippard, in platinum chemistry. BTP-114 is a novel personalized cisplatin prodrug designed with the modern insights from cancer biology, genomics and targeting. BTP-114 is a new chemical entity which accumulates in tumor tissue resulting in dramatically increased levels of DNA bound platinum, achieving a concentrated therapeutic effect at the site of cancer.
Blend is rapidly developing its pipeline of innovative cancer therapeutics. With the Pentarin platform, we are developing an internal pipeline of proprietary drug conjugates, and the platform also serves as the foundation for developing Pentarins using the targeting scaffolds of pharmaceutical collaborators.
Blend was founded by three leaders in the fields of nanomedicine and chemistry from the Brigham and Women’s Hospital (BWH)–Harvard Medical School (HMS), and Massachusetts Institute of Technology (MIT): Dr. Omid Farokhzad of BWH–HMS, and Dr. Robert Langer and Dr. Stephen J. Lippard of MIT. The company has attracted top-tier investors including Flagship Ventures, NanoDimension and New Enterprise Associates.